News & Insights
Stay Informed With Our Latest Updates
Explore our comprehensive collection of news and in-depth insights spanning practice areas, industries, and regions.
Firm News March 3, 2026
Gibson Dunn Advises Gyre Therapeutics on Its Acquisition of Cullgen
Gibson Dunn is advising Gyre Therapeutics, Inc., an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic diseases, on its acquisition of Cullgen Inc.
Firm News December 17, 2025
Gibson Dunn Advising Yarrow Bioscience on Merger with VYNE Therapeutics and Concurrent $200 Million Financings
Gibson Dunn is advising Yarrow Bioscience on its merger with VYNE Therapeutics and concurrent $200 million financings
Firm News November 19, 2025
Gibson Dunn Advising XOMA Royalty on XenoTherapeutics and Xeno Acquisition’s Purchase of Repare Therapeutics
Gibson Dunn is advising XOMA Royalty on XenoTherapeutics, Inc. and Xeno Acquisition Corp.’s acquisition of Repare Therapeutics Inc.
Firm News November 12, 2025
Gibson Dunn Advising Damora Therapeutics on Sale to Galecto and on $285 Million Private Placement by Galecto
Gibson Dunn is advising privately held biotechnology company Damora Therapeutics, Inc. on its sale to Galecto, Inc.
Firm News August 21, 2025
Gibson Dunn Advises XOMA Royalty on Acquisition of Mural Oncology
Gibson Dunn is advising XOMA Royalty Corporation on its acquisition of Mural Oncology plc
Firm News August 15, 2025
Gibson Dunn Represents RTW Investments in Acquisition of Synthetic Royalty Interest in Anaphylm™
Gibson Dunn is representing RTW in its acquisition from Aquestive Therapeutics of a synthetic royalty interest in Anaphylm™ (epinephrine) Sublingual Film, and in its acquisition of Aquestive common stock as the lead investor in the company’s $85 million underwritten offering
Firm News August 13, 2025
Gibson Dunn Represented XOMA Royalty in Its Acquisition of LAVA Therapeutics
Gibson Dunn represented XOMA Royalty Corporation in its acquisition of clinical-stage immuno-oncology company LAVA Therapeutics N.V.
Firm News July 23, 2025
Gibson Dunn Represented XOMA Royalty in the Acquisition of ESSA Pharma by XenoTherapeutics
Gibson Dunn represented XOMA Royalty Corporation in connection with the acquisition of ESSA Pharma Inc. by XenoTherapeutics, Inc.